Hims & Hers Health (NYSE:HIMS) Shares Up 1.9% - Still a Buy?

Key Points

• Hims & Hers Health shares rose by 1.9%, closing at $44.85, despite trading volume significantly below average.
• Analyst ratings for the stock are mixed, with two "Buy" ratings, eight "Hold" ratings, and three "Sell" ratings, resulting in a consensus target price of $38.92.
• The company reported a 72.6% increase in revenue year-over-year, but missed earnings expectations with $0.17 earnings per share compared to the consensus of $0.18.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report)'s stock price shot up 1.9% during trading on Thursday . The stock traded as high as $45.02 and last traded at $44.85. 5,761,773 shares traded hands during trading, a decline of 83% from the average session volume of 33,341,141 shares. The stock had previously closed at $44.01.

Analyst Ratings Changes

Several brokerages recently commented on HIMS. Truist Financial reduced their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a research note on Monday, August 18th. Needham & Company LLC reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Zacks Research cut shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Piper Sandler reaffirmed a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Finally, Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Reduce" and a consensus target price of $38.92.

Hims & Hers Health Trading Up 1.4%

The stock has a market capitalization of $10.08 billion, a P/E ratio of 55.84, a price-to-earnings-growth ratio of 3.06 and a beta of 2.08. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The stock's fifty day moving average price is $50.76 and its two-hundred day moving average price is $45.84.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The business had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company's revenue was up 72.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the transaction, the insider directly owned 169,940 shares of the company's stock, valued at approximately $9,105,385.20. The trade was a 26.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael Chi sold 17,102 shares of the business's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the transaction, the insider directly owned 278,654 shares in the company, valued at approximately $16,649,576.50. The trade was a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,383,847 shares of company stock valued at $71,247,924 in the last 90 days. 13.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. Thrivent Financial for Lutherans boosted its stake in Hims & Hers Health by 3.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 46,444 shares of the company's stock worth $2,315,000 after purchasing an additional 1,617 shares in the last quarter. Marex Group plc bought a new position in Hims & Hers Health in the 2nd quarter worth about $53,626,000. Nomura Holdings Inc. boosted its stake in Hims & Hers Health by 151.4% in the 2nd quarter. Nomura Holdings Inc. now owns 161,052 shares of the company's stock worth $8,028,000 after purchasing an additional 96,997 shares in the last quarter. Castleark Management LLC bought a new position in Hims & Hers Health in the 2nd quarter worth about $2,921,000. Finally, Tower Research Capital LLC TRC boosted its stake in Hims & Hers Health by 54.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 38,285 shares of the company's stock worth $1,909,000 after purchasing an additional 13,473 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.